Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Presepsin Proposed as 'Robust' Biomarker of Early-Onset Sepsis

By LabMedica International staff writers
Posted on 08 Jun 2022

Neonatal early-onset sepsis (EOS) is a severe disease, particularly in preterm infants. More...

Timely diagnosis can be challenging owing to unspecific presentation and questionable performance of the common markers of infection.

Presepsin (P-SEP), the newly identified infection biomarker, is a 13 kDa fragment of the N-terminal of soluble CD14 and is released into the blood upon the activation of monocytes in response to infection. The accuracy of presepsin for the diagnosis of neonatal early-onset sepsis has been examined.

Neonatologists at the Careggi University Hospital (Florence, Italy) and their colleagues performed a literature search for studies involving term or preterm infants diagnosed with EOS, which examined presepsin levels (and measured sensitivity/specificity) during workup for suspected cases. Outcomes of interest for both the primary and secondary analysis (either clinical or culture-proven sepsis) were sensitivity, specificity and diagnostic odds ratio.

In all, 12 studies involving 828 newborns (including 460 with EOS and the rest uninfected) met inclusion criteria for the primary analysis. Ten of the studies included a mix of EOS and LOS, four only included infants born at term, two were restricted to preterm infants, and the rest had a mix. Half of the studies were performed in Egypt, while the remaining were conducted in Europe and Asia. The secondary analysis included 23 studies that met the broader criteria and involved 1,866 newborns (including 1,040 newborns with EOS and the rest uninfected), with seven of the trials involving only newborns with EOS.

The investigators reported presepsin accuracy was not associated with gestational age, measurement with chemiluminescence enzyme immunoassay or enzyme-linked immunosorbent assay testing, country where the study was performed, or risk of bias judgment. In the secondary analysis, among 23 studies and 1,866 newborns, accuracy was significantly associated with only test type. In the primary analysis, among 12 studies and 828 newborns of any gestational age, pooled sensitivity and specificity were 0.93 (95% CI, 0.86-0.95) and 0.91 (95% CI, 0.85-0.95), respectively; pooled diagnostic odds ratio was 131.69 (95% CI, 54.93-310.94). Subgroup analysis showed that presepsin specificity was associated with the inclusion of only EOS or all neonatal sepsis.

Chiara Poggi, MD, PhD, a Neonatologist and senior author of the study, said, “EOS diagnosis is a frequent challenge in the neonatal intensive care unit, as clinical signs are equivocal and the common markers of infection, such as C-reactive protein and procalcitonin, physiologically increase during the first 48 hours of life in response to non-infective stimuli.”

The authors concluded that their systematic review and meta-analysis suggest that presepsin was an accurate biomarker of EOS. Clinical trials are warranted to assess its usefulness and safety to reduce early antibiotic exposure, particularly in preterm newborns. The study was published on May 31, 2022 in the journal JAMA Pediatrics.

Related Links:
Careggi University Hospital


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
Urine Chemistry Control
Dropper Urine Chemistry Control
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.